Japan· JP-4291424A1020
ペルツズマブ（遺伝子組換え）
A pertuzumab product containing ペルツズマブ（遺伝子組換え）, registered in Japan by 中外製薬, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Pertuzumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FD02 (pertuzumab), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Pertuzumab · ATC L01FD02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ペルツズマブ（遺伝子組換え）
- Manufacturer
- 中外製薬
- Country
- Japan (JP)
- ATC code
- L01FD02
- ATC class
- Pertuzumab
- Defined daily dose
- 20 mg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for pertuzumab.
Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pertuzumab · interactions on record
2 records
- 2 moderate
Most severe, free to view
- IdelalisibL01EM01moderate
- IdelalisibL01XX47moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pertuzumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainPERJETA 420 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- FinlandPerjeta2care4 ApS
- BelgiumPerjeta 420 mgRoche Registration
- United KingdomPerjeta 420mg/14ml concentrate for solution for infusion vialsRoche Products Ltd
- CzechiaPERJETARoche Registration GmbH, Grenzach-Wyhlen
- IrelandPerjeta 420 mg concentrate for solution for infusionRoche Registration GmbH
- IcelandPerjetaRoche Registration GmbH*
- NetherlandsPerjeta, 420 mg Concentraat voor oplossing voor infusieRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Perjeta, Poherdy
- Liechtenstein · Perjeta, Poherdy
- Norway · Perjeta, Poherdy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/18673f3c-b95a-4e56-b108-3cbb01f9a95e GET /v1/drugs/18673f3c-b95a-4e56-b108-3cbb01f9a95e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "４２０ｍｇ１４ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291424A1020",
"category": "注射薬",
"price_yen": 206472,
"generic_name": "ペルツズマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about pertuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.